GNH USA

Europe — EMA

Mitoxantrona Pharmis (Mitoxantrone)

GNH USA supplies Mitoxantrona Pharmis (Mitoxantrone), an antineoplastic therapy for acute myeloid leukemia, metastatic breast cancer and prostate cancer.

Mitoxantrone

Request sourcing

1
Pack/s

What is Mitoxantrone?

Mitoxantrone, the active ingredient in Mitoxantrona Pharmis, is a anthracenedione antineoplastic presented as a injectable solution for intravenous use. It is employed in the treatment of acute myeloid leukemia, metastatic breast cancer and prostate cancer in adult patients. It is indicated for use in adult patients with these malignancies and is administered under specialist supervision.

GNH USA supplies Mitoxantrona Pharmis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

What is Mitoxantrone used for?

Mitoxantrone is used in the treatment of hematologic malignancies and selected solid tumors.

Acute myeloid leukemia: induces remission and prolongs survival in adult patients. Metastatic breast cancer: provides disease control after prior therapies. Prostate cancer: offers therapeutic benefit in hormone‑refractory disease.

What are the side effects of Mitoxantrone?

Mitoxantrone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness during treatment. - Alopecia: reversible hair loss. - Myelosuppression: decreased blood cell counts, leading to anemia or neutropenia. - Vomiting: occasional episodes of emesis. - Mucositis: inflammation of oral mucosa causing discomfort.

Serious or Rare Side Effects: - Cardiotoxicity: potential for reduced left ventricular ejection fraction. - Secondary malignancies: risk of therapy‑related leukemia. - Severe infection: due to profound neutropenia.

What precautions apply to Mitoxantrone?

When using Mitoxantrone, clinicians should observe specific precautions to minimise risks. - Cardiac monitoring: perform baseline and periodic echocardiograms. - Hematologic assessment: monitor complete blood count before each dose. - Renal function: evaluate creatinine clearance in patients with kidney impairment. - Concomitant drugs: avoid concurrent use with other DNA‑damaging agents unless necessary. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Mitoxantrone interact with?

Mitoxantrone can interact with several medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Anthracyclines: combined use markedly increases cardiotoxicity. - Live vaccines: immunosuppression may lead to severe infection.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., ketoconazole): may raise plasma levels. - CYP450 inducers (e.g., rifampin): may reduce therapeutic effect. - Anticoagulants (e.g., warfarin): enhanced bleeding risk due to platelet suppression.

Frequently asked questions

What conditions is Mitoxantrona Pharmis used to treat?+
Mitoxantrona Pharmis contains mitoxantrone, which is indicated for the treatment of acute myeloid leukemia, metastatic breast cancer and hormone‑refractory prostate cancer in adult patients. It is administered by a qualified oncology specialist as part of a chemotherapy regimen.
How does mitoxantrone work against cancer cells?+
Mitoxantrone intercalates into DNA and stabilises the topoisomerase II‑DNA complex, preventing the enzyme from resealing DNA strands. This creates double‑strand breaks, triggers cell‑cycle arrest and activates apoptotic pathways, leading to selective death of rapidly dividing tumour cells.
What is the usual dose of Mitoxantrona Pharmis?+
The dose of mitoxantrone is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function and prior therapies. Only a qualified healthcare professional should determine the dosing schedule.
Is Mitoxantrona Pharmis safe during pregnancy or breastfeeding?+
The safety of mitoxantrone in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant, and the decision should be made by a specialist.
How do I order Mitoxantrona Pharmis from GNH USA?+
To request Mitoxantrona Pharmis, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.
How does mitoxantrone compare with other chemotherapy agents?+
Mitoxantrone belongs to the anthracenedione class and differs from anthracyclines such as doxorubicin by having a distinct DNA‑intercalating profile and a lower incidence of certain cardiac toxicities. However, it shares risks like myelosuppression and requires careful monitoring, making the choice of agent dependent on the tumour type and patient tolerance.
What are the storage and handling requirements for Mitoxantrona Pharmis?+
Mitoxantrona Pharmis must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, must not be frozen or shaken, and should be used within the stability period indicated by the manufacturer.
How is Mitoxantrona Pharmis administered?+
The product is supplied as an injectable solution for intravenous infusion. Administration is performed by trained healthcare professionals in a clinical setting, typically over a defined period according to the prescribed chemotherapy protocol.
What are the most serious risks associated with Mitoxantrona Pharmis?+
Serious risks include cardiotoxicity leading to reduced heart function, secondary malignancies such as therapy‑related leukemia, and severe infections due to profound neutropenia. Patients should be monitored closely for cardiac symptoms, blood counts and signs of infection throughout treatment.
Who should not receive Mitoxantrona Pharmis?+
Mitoxantrona Pharmis is contraindicated in patients with known hypersensitivity to mitoxantrone or any component of the formulation, in those with uncontrolled cardiac disease, and in pregnant or nursing women unless the therapeutic benefit justifies the potential risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Mitoxantrone
Route
Intravenous Use
Manufacturer
Pharmis Biofarmacêutica, Lda.
Origin
EU

Related products

Mitoxan

Mitoxan

Mitoxantrone

Medicamerc S.A
EU
Mitoxantron "ebewe"

Mitoxantron "ebewe"

Mitoxantrone

Ebewe Pharma
EU
Mitoxantron Accord

Mitoxantron Accord

Mitoxantrone

Accord Healthcare B.V.
EU
Mitoxantron Ebewe

Mitoxantron Ebewe

Mitoxantrone

Ebewe Pharma
EU